Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Perspectives on Payer Engagement Strategies

Posted by Matt Breese on Sep 19, 2017

Successful life science companies often customize their payer engagement strategies. This method improves payer relationships and may also lead to more innovative and effective therapies.

In fact, a recent survey revealed that 70% of managed care executives recognize that there is value in the early stage collaboration between payers and biopharma companies. 

Read More

Topics: Industry Trends, Payer

MMIT Reality Check on HIV (Aug 2017)

Posted by Matt Breese on Aug 11, 2017

According to our recent payer coverage analysis for HIV treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

Perspectives on Payer Market Events

Posted by Matt Breese on Aug 8, 2017

The healthcare environment is ever-changingBeing able to understand the drivers and predictions around major payer market events is only one component of market access. Pharma brands may also need to adjust their marketing approach based on market events.

Having an educational framework in place for field sales teams can help these individuals prepare for HCP engagements. With a solid understanding of the environment and clear messaging guidelines, pharma reps are more equipped to address market changes. Timely promotional assets can be used to ensure your brand team remains credible.

Read More

Topics: Market Access, Payer

Trends That Matter for Off-Label Drug Use

Posted by Matt Breese on Aug 3, 2017

In our weekly Trends that Matter series, we provide engaging infographics, articles and recent news from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is payers' views on off-label drug use.

Once medications are approved by the FDA and on the market, the FDA does not control how physicians prescribe them. According to the FDA, "Healthcare providers generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient."

Read More

Topics: Industry Trends, Payer

MMIT Reality Check on Multiple Sclerosis (Jun 2017)

Posted by Matt Breese on Jun 29, 2017

According to our recent payer coverage analysis for multiple sclerosis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

MMIT Reality Check on Hemophilia (Jun 2017)

Posted by Matt Breese on Jun 21, 2017

According to our recent payer coverage analysis for hemophilia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

MMIT Reality Check on G-CSF (Jun 2017)

Posted by Matt Breese on Jun 16, 2017

According to our recent payer coverage analysis for G-CSF treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

Note from the Editor: due to the importance of medical benefit for G-CSF, we've updated this reality check to include a snapshot of market access across medical benefit.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

MMIT Reality Check on Heart Failure (Jun 2017)

Posted by Matt Breese on Jun 14, 2017

According to our recent payer coverage analysis for chronic heart failure treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

MMIT Reality Check on Dermatology: Acne (June 2017)

Posted by Matt Breese on Jun 2, 2017

According to our recent payer coverage analysis for dermatology-acne, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

Perspectives on Simplifying Reimbursement Restrictions

Posted by Matt Breese on Apr 11, 2017

In upcoming years, specialty drugs sales are expected to rise, accounting for nearly half of all drug sales in the US, according to HIT Consultant.  Specialty drugs typically require special handling, which makes these medications more expensive than other treatment options. As a result, payers use complex restrictions such as prior authorizations and step therapies (PA/ST) to reduce their costs. HCPs must apply for approval on an individual basis to get coverage for certain specialty drugs.

Pharma marketers can aid in the reimbursement process by reducing confusion around restrictions. Reps that have a comprehensive understanding of their brand’s restrictions can communicate them more clearly to prescribers. This shared understanding increases the likelihood HCPs will write prescriptions for their brand. 

Read More

Topics: Payer, Branding & Marketing